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Huntington’s disease (HD) is a fatal neurodegenerative disease characterized pathologically by aggregates
composedofN-terminalfragmentsofthemutantformoftheproteinhuntingtin(htt).TheroleoftheseN-terminal
fragments in disease pathogenesis has been questioned based in part on studies in transgenic mice. In one
important example, mice that express an N-terminal fragment of mutant htt terminating at the C-terminus of
exon 2 (termed the Shortstop mouse) were reported to develop robust inclusion pathology without developing
phenotypic abnormalities seen in the R6/2 or N171-82Q models of HD, which are also based on expression of
mutant N-terminal htt fragments. To further explore the capacity of mutant exon-2 htt fragments to produce
neurologic abnormalities (N-terminal 118 amino acids; N118), we generated transgenic mice expressing
cDNA that encodes htt N118-82Q with the mouse prion promoter vector. In mice generated in this manner,
we demonstrate robust inclusion pathology accompanied by early death and failure to gain weight. These phe-
notypes are the most robust abnormalities identiﬁed in the R6/2 and N171-82Q models. We conclude that the
lack of an overt phenotype in the initial Shortstop mice cannot be completely explained by the properties of
mutant htt N118 fragments.
INTRODUCTION
Huntington’s disease (HD) is a genetic, fatal, neurodegenera-
tive disorder with symptoms that include movement, cognitive
and psychiatric abnormalities (reviewed in 1). The HD
mutation is an expansion of a polyglutamine (polyQ) tract in
the ﬁrst of 67 exons of the huntingtin (htt) gene; expansion
of the repeat beyond 40 consecutive glutamines invariably
causes the disease (2). Post-mortem analysis of human HD
brains shows marked widespread atrophy, with notable cell
loss in the striatum and cortex (3,4). Neurons throughout the
central nervous system develop cellular pathology that con-
sists of ubiquitinated, nuclear and cytoplasmic inclusions
(5,6). This inclusion/aggregate pathology has also been
observed in transgenic mice (7–9), knock-in mice (10–12)
and numerous cell culture models (13–16). The pathologic
inclusions are composed of a small N-terminal cleavage
product of mutant htt that is thought to terminate N-terminal
to amino acid 115 [this fragment has been referred to as clea-
vage product-A (Cp-A) or cleavage product-1] (16–19). Many
studies have documented that N-terminal fragments of mutant
htt are more prone to aggregate and are more toxic to cultured
cells than full-length mutant htt (13,20,21).
Studies of mouse models of HD have provided evidence that
favored the view that N-terminal fragments of mutant htt could
be mediators of toxicity. The R6/2 mouse model expresses the
ﬁrst exon of human htt (amino acids 1–90) with  140Q and
exhibits inclusion pathology (7), accompanied by brain
atrophy (22), motor deﬁcits (23), a failure to thrive and prema-
ture death (24). Similar phenotypes were observed in mice
expressing the ﬁrst 171 amino acids of htt with 82 glutamine
repeats (8,25). Notably, the N171-82Q fragment is cleaved to
produce a small Cp-A-like fragment that ultimately produces
intranuclear and cytoplasmic aggregates (17). The YAC128
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exons) butultimately developinclusion pathology composed of
smallhttN-terminalfragments(26,27).Additionally,micewith
an expanded polyQ knocked-in to their endogenous htt allele
develop inclusion pathology containing smaller N-terminal
fragmentsofmutanthtt(19).Neithertheyeastartiﬁcialchromo-
some (YAC), bacterial artiﬁcial chromosome, nor knock-in
models show abbreviated lifespans. A recent comparison of
knock-in (HdhQ150) and R6/2 mice showed that the behavioral
impairments and aggregate deposition of the HdhQ150 mice
were similar to those of the R6/2 but developed later and pro-
gressed more slowly (28). Collectively, these studies suggest a
linkagebetweenthegenerationofN-terminalcleavageproducts
of mutant htt, inclusion pathology and neurologic toxicity.
However, in 2005, Slow et al.( 9) described transgenic
mice (termed ‘Shortstop’ mice) expressing the ﬁrst two
exons (amino acids 1–118) of human htt with 120Q that
developed widespread inclusion pathology but exhibited no
behavioral abnormalities, normal lifespans and no brain
atrophy. The Shortstop mice were created when a fragment
of a mutant htt YAC, which encompasses the htt promoter,
the ﬁrst two exons and part of the second intron, integrated
in a manner to produce a truncated protein. The shortstop
fragment is produced because the second intron contains an
in-frame stop codon just downstream of the 3′ splice donor
site of exon 2 with a cryptic poly-adenylation site further
downstream. The resulting mRNA transcript codes for an
htt fragment that would correspond to the ﬁrst 118 amino
acids of normal htt (23Q base). Because the same YAC
that was injected to produce Shortstop mice has been used
to produce mice that express full-length mutant htt, which
develop motor function deﬁcits and brain atrophy, Slow
et al.( 9) suggested that the N118 fragment of mutant htt
may be less toxic than full-length htt. The N118 shortstop
fragment is similar in length to, but not identical to, the afore-
mentioned Cp-A fragment that appears to produce the
inclusion pathology of HD. The Cp-A fragment terminates
between residues 105 and 114 and thus is slightly shorter
than the shortstop fragment (16,17). In cultured cell models
of mutant htt toxicity, expression of N118-120Q was reported
to produce less activation of caspase 3 than expression of
N171-82Q constructs, suggesting that the N118 fragment is
less toxic (21). Notably, the N171-82Q fragment is cleaved
to produce a Cp-A-sized fragment, which produces inclusions
in mice and cell culture models (17). Thus, whether the
speciﬁc length of the N118 fragment reduced its toxicity
was in question.
In the present study, we sought to further investigate the
relative toxicity of the shortstop htt fragment in transgenic
mice. In designing the experiment, we chose to construct
htt N118 cDNA genes with 82 glutamines to express via
the mouse PrP.Xho vector so that the new mice could be
compared with existing N171-82Q mice (8). We found
that mice expressing N118-82Q via the mouse PrP.Xho
vector exhibit pathological and behavioral phenotypes
similar to the R6/2 and N171-82Q mice. While these data
do not directly indicate that aggregates themselves are
pathogenic, they support the body of the literature
showing that truncated forms of mutant htt produce neuro-
logical abnormalities in vivo. We conclude that the basis
for the lack of overt phenotypes in the Shortstop mice
described by Slow et al.( 9) is not explained by the speciﬁc
length of the fragment.
RESULTS
Generation of transgenic mice
In creating the N118-82Q mice, we developed a means to visu-
ally genotype transgenic animals. We engineered a reporter
transgene, encoding enhanced green ﬂuorescent protein
(eGFP), that was designed to be co-injected with htt
N118-82Q transgene constructs. The eGFP reporter was con-
structed by inserting the cDNA into a vector harboring a
keratin-14 (K14) promoter to drive expression of eGFP in
skin. The K14 vector was created by removing the promoter
element of the MoPrP.Xho vector and replacing it with a 2 kb
fragment of the human keratin-14 gene (Supplementary
Material, Fig. S1). A strategy similar to this approach was
used previously to produce a vector that can be regulated by
tetracycline analogs (29). Previous studies have shown that
co-injection of two independent transgenes results in
co-integration of the transgenes at a single locus (30,31). In
our experience, the two transgenes are so closely integrated
thatrecombinationtosegregatethegenesvirtuallyneveroccurs.
To test the toxicity of mutant N118 htt fragments, we pro-
duced cDNA encoding htt N118 with an 82Q repeat
(N118-82Q) and inserted the cDNA into the MoPrP.Xho
vector for embryo injection (32). N118-82Q encodes the ﬁrst
two exons of htt; amino acid numbering uses a 23Q base
(NCBI Reference Sequence: NM_002111). This construct
was co-injected with the K14-eGFP construct (mice hence-
forth referred to as HD118-eGFP). In parallel, we generated
strains of mice that harbor the K14-eGFP construct alone
and mice that were co-injected with K14-eGFP and
Mo.PrP-N171-82Q constructs (mice henceforth referred to as
HD171-eGFP). These two constructs provided negative and
positive controls, respectively. The Mo.PrP-N171-82Q con-
struct is identical to a construct used previously to produce
HD-N171-82Q line 81 mice (8), to which we compare the
new lines of mice that are now described. Using goggles
ﬁtted with the appropriate ﬁlters to visualize eGFP expression,
we could reliably distinguish transgenic mice from non-
transgenic (NTg) mice. To illustrate, we captured an image
of newborn mice in a Fuji imager (Supplementary Material,
Figure 1. The K14-eGFP transgene is expressed in the skin and at low levels
in the brain. Each lane contains 10 mg of detergent soluble protein as described
in Materials and Methods. Immunoblots were probed with anti-GFP antibody
clone mJL-8 and visualized by chemiluminescence on a Fuji imaging system.
Spinal cord (S.C.). The image shown is representative of three replications.
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is most visible in ears, paws and tail skin. To determine
whether the eGFP was only expressed in skin, we performed
immunoblot analysis of various tissues. As expected, eGFP
was easily detected in the skin from an ear biopsy (Fig. 1).
No other tissue expressed eGFP except for a weak signal in
brain lysates. In sagittal brain sections from several indepen-
dent strains of mice harboring the K14-eGFP transgene,
eGFP was detectable in multiple regions of the brain with
the highest level usually found in the forebrain and cerebellum
(Supplementary Material, Fig. S3). However, we did note
some variability within mice of the same strain as the intensity
of eGFP in different structures varied between mice. Mice har-
boring the K14-eGFP transgene alone appeared normal
throughout their lifespan (out to .530 days at the time of
writing). We note that numerous lines of mice expressing ﬂu-
orescent proteins in the central nervous system (CNS) have
been generated and reported to be free of abnormalities
(33–35). Thus, we were conﬁdent that some expression of
the eGFP reporter in the brain would be unlikely to affect
the outcome of our study of N118-82Q expression while sim-
ultaneously allowing rapid identiﬁcation of transgenic mice.
Identifying HD118-eGFP founders
In generating HD118-eGFP mice, we initially identiﬁed 10
founders that harbored the htt transgene, detected in
genomic DNA from tail-biopsy, and they all expressed
varying levels of eGFP in skin. Several founders that were
among those with the most ﬂuorescent skin died prematurely
before producing offspring. However, we were able to estab-
lish three lines to breed cohorts for downstream analysis.
Northern blot analyses of brain RNA were performed to
compare relative expression levels of transgene mRNA
among these new lines of mice and to compare the levels to
our previously established HD-N171-82Q line 81 mice (8),
which do not harbor the K14-eGFP transgene. Of the three
breeding lines of HD118-eGFP mice, the line designated
S22 expressed the highest level of htt; however, the level
was  50% lower than that of HD-N171-82Q line 81 mice
(Fig. 2A). Immunoblot analyses of brain lysates from young
HD118-eGFP mice conﬁrmed expression of the N118-82Q
protein in the brain and that line S22 expressed the highest
levels (Supplementary Material, Fig. S4). Lines S32 and S12
were terminated due to low expression levels. Northern blots
were also performed to determine the levels of transgene
mRNA in the brains of the newly generated HD171-eGFP
mice. In all cases, the level of transgene mRNA in the
brains of the HD171-eGFP mice was at least 50% lower
than that of the HD-N171-82Q line 81 mice (Fig. 2B). We
chose to further evaluate three lines of HD171-eGFP mice,
designated HD171-eGFP#2, #3 and #7. HD171-eGFP#8
mice were discontinued due to low expression.
Behavioral phenotype of HD mice
HD118-eGFP line S22 mice exhibited an early failure to thrive
and premature death at 138.5+11.9 days (SEM; n ¼ 12)
(Fig. 3). Two mice lived almost twice as long as the majority,
which may be a result of loss of copy number (blue line of
Fig. 3, .200 days). The new lines of HD171-eGFP mice
developed phenotypes similar to the line S22 mice, but at
much later ages. The HD171-eGFP#2 mice have lifespans of
about 648.8+18.6 (SEM; n ¼ 11) days of age (Fig. 3). The
Figure 2. Northern blot analysis of transgene mRNA. (A) The top portion of the ﬁgure shows the level of N118-82Q mRNA in different lines of mice (S12, S22
and S32). NTg and N171-82Q (line 81) serve as relative controls ranging from no expression (NTg) to maximum achieved (line 81). (B) The top portion of the
ﬁgure shows the level of N171-82Q mRNA in new lines of HD171-eGFP mice (lines #2, #3, #7 and #8). The bottom portion of each ﬁgure shows the UV image
of the formaldehyde/agarose gel to demonstrate the levels of 28S RNA. The membranes were probed with radiolabeled htt cDNAs as described in Materials and
Methods. The image shown is representative of two replications.
Figure 3. Life expectancy of HD118-eGFP and HD171-eGFP mice. A
Kaplan–Meier plot of line S22 (blue line) shows that this line of mice dies
prematurely. After  100 days, the percentage of mice that survive gradually
decreases (mean ¼ 138.5+11.9 days, SEM, n ¼ 12). Mice from
HD171-eGFP line #2 (black line) live substantially longer (mean ¼ 648.8+
18.6 days, SEM, n ¼ 11).
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recently and we have limited data on life expectancy. We
have observed HD-related abnormalities and early death in
the HD171-eGFP#3 mice at about 12 months of age. The
founder for HD171-eGFP#7 mice died at 8 months of age.
The general appearance of the HD171-eGFP#2 mice was
similar to that of the previously described HD-N171-82Q
line 81 mice (8) in that observed phenotypes included
failure to gain weight and hypoactivity towards the end of
life expectancy.
Similar to the previously described HD-N171-82Q line 81
mice, the HD118-eGFP line S22 mice failed to gain weight
(Fig. 4A). Line S22 mice were indistinguishable from their
NTg littermates until weaning stage ( 28 days), at which
point they began to gain less weight. By end-stage, transgenic
line S22 mice weighed less than half of their NTg littermates
(NTg, 40.54+2.39 g, n ¼ 7 versus S22, 17.88+0.64 g,
n ¼ 7). End-stage was generally deﬁned by criteria similar
to what we use for the HD-N171-82Q mice, which included
decreased body weight and failure to ambulate upon prodding
(Supplemental Information, Video S1). Brains from end-stage
line S22 mice weighed signiﬁcantly less than NTg littermates
(Fig. 4B, NTg, 0.479+0.007 g, n ¼ 7 versus S22, 0.360+
0.004 g, n ¼ 4).
Neuropathology of HD118-eGFP mice
One of the pathologic hallmarks of human HD is cytoplasmic
and intranuclear inclusions that are immunoreactive to both htt
and ubiquitin (5,6). To assess whether line S22 mice recapitu-
lated this inclusion pathology, we performed immunohisto-
chemistry on brain sections and compared those results to
line 81 mice expressing N171-82Q and the HD171-eGFP#2
mice. As expected, the brains of S22 mice showed abundant
inclusion pathology in multiple brain structures (Fig. 5). In
comparison to the pathology of HD-N171-82Q line 81 mice
and HD171-eGFP#2 mice, the inclusions in the brains of the
line S22 mice were larger, more heterogeneous in size and
more obvious or frequent in cytosol (Fig. 6). The inclusions
in lines 81 and HD171-eGFP#2 were of approximately the
same size and almost exclusively in the nucleus (Fig. 6A
and B). In the HD118-eGFP mice, extranuclear inclusions
were more frequent and obviously larger (Fig. 6C). In all
three cases, inclusions were usually immunoreactive for ubi-
quitin (Fig. 6). We also analyzed the brain pathology of
mice from lines S12 and S32, and of the three founders that
reached end-stage before reproducing. No pathology was
evident in mice from lines S12 and S32 (Supplementary
Material, Fig. S5), which express very low levels of transgene
mRNA. However, the brains of the three founders (designated
S23, S31 and S43) that showed early symptoms also showed
inclusion pathology with features similar to the line S22
mice (Supplementary Material, Fig. S5).
DISCUSSION
In the present study, we have examined whether an N-terminal
fragment of htt that terminates at residue 118 with 82 consecu-
tive glutamines produces neurologic abnormalities when
expressed in the brains of transgenic mice. Several animals
expressing this transgene failed to thrive and died before
breeding. However, we were able to establish one line of
breeding animals that express the htt N118-82Q transgene at
levels that approach that of previously described
HD-N171-82Q line 81 mice (8). To ease the identiﬁcation of
these new transgenic animals, we co-injected the
PrP-N118-82Q transgene construct with a K14-eGFP trans-
gene construct, which expressed eGFP at high levels in skin.
The phenotypes of these HD118-eGFP mice were generally
identical to what has previously been described in
HD-N171-82Q mice (Table 1)( 8). Overt phenotypes included
failure to gain weight, poor grooming, hypoactivity and pre-
mature death. In previous studies of HD-N171-82Q line 81
mice, we have described modest to moderate deﬁcits in the
ability to perform rotarod tasks (8,25). Because the rotarod
deﬁcits in the HD-N171-82Q line 81 mice are relatively
modest, we chose to focus on the most robust phenotypes,
which include early death, failure to gain weight, brain
atrophy and inclusion pathology. Pathologically, the
HD118-eGFP mice were similar to the HD-N171-82Q mice
in that there was no overt evidence of neurodegeneration or
cell loss, but there was a signiﬁcant reduction in brain
weight indicating general atrophy. Neurons throughout the
brain contained htt and ubiquitin immunoreactive inclusion
pathology. A subtle difference between the HD118-eGFP
and HD-N171-82Q mice was that in the HD118-eGFP mice
the inclusions were generally larger, more heterogeneous in
size and more visible in neuropil. Overall, we conclude that
expression of a mutant htt fragment that encompasses the
ﬁrst two exons of htt produces phenotypes similar to our pre-
viously described HD-N171-82Q line 81 mice (8) and the R6/
2 model of HD (24).
In generating the N118-82Q mice, we employed a new tech-
nology in which we co-injected the htt transgene construct
(PrP-N118-82Q) with a construct for expression of eGFP in
skin (K14-eGFP). Although the eGFP was highest in skin,
we did observe some expression of eGFP in the brain. In par-
allel to generating the HD118-eGFP mice, we produced lines
Figure 4. HD118-eGFP mice show reduced body and brain weights. (A) Age-
matched NTg (white bars) body weight was 40.54+2.39 g (n ¼ 7), more
than twice as much as line S22 mice (lined bars) at end-stage, 17.88+0.64 g
(n ¼ 7, unpaired t-test P , 0.0001). (B) Average brain weight for NTg mice
immediately after harvesting was 0.479+0.007 g (n ¼ 7). Line S22 mice had
a signiﬁcantly reduced brain weight at 0.360+0.004 g (n ¼ 4, unpaired t-test
P , 0.0001).
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K14-eGFP constructs. All of these mice were compared with
a previously generated line of mice that harbor the same
PrP-N171-82Q construct used in the co-injection studies
described here. The two new lines of HD-N171-82Q +
eGFP mice we describe here (HD171-eGFP#2 and
HD171-eGFP#3) show much longer life expectancies when
compared with the original HD-N171-82Q line 81 mice. The
difference in time to death between the two HD171-eGFP
lines of mice and the HD-N171-82Q line 81 mice can be
explained by the level of mutant htt expression. The levels
of htt transgene mRNA in the HD171-eGFP lines was
observed to be 30–50% lower than that of the line 81 mice.
Although the levels of htt mRNA in the HD118-eGFP mice
were comparable with the HD171-eGFP mice, the lifespan
of the HD118-eGFP mice was considerably shorter than all
of the lines of the HD171-eGFP lines of mice we produced.
Thus, we conclude that the N118-82Q fragment is more
toxic than the N171-82Q fragment.
Our original impetus in generating the HD118-eGFP mice
we describe here was a report by Slow et al.( 9) that described
mice that were transgenic for a fragment of human genomic
DNA derived from a YAC of the mutant htt gene. Upon inte-
gration, most of the coding sequence of htt was lost such that
only the ﬁrst two exons with a portion of the downstream
intron were integrated in the genome. This DNA fragment is
transcribed to produce an mRNA that in turn produces an N-
terminal fragment of mutant (120Q) human htt that encom-
passed the ﬁrst two exons, which equates to a termination at
amino acid 118. A line of mice was developed and examined
that was termed the Shortstop mouse (9). In contrast to the
HD118-eGFP mice we describe here, the Shortstop mouse
does not exhibit premature death or any other
disease-associated phenotypes (Table 1)( 9). The Shortstop
mice were originally compared with mice harboring a YAC
of the entire human htt gene with the same length repeat
expansion (YAC128 mice). The YAC128 mice show motor
deﬁcits, reduced striatal volume and reduced brain weight by
12 months of age (9). In comparison to the YAC128 mice,
the Shortstop mice show none of these phenotypes.
In comparing our new HD118-eGFP mice and the Shortstop
mice, there are obvious differences in the way the mice were
Figure 5. Inclusion pathology was observed in many brain regions in end-stage HD118-82Q line S22 mice. Htt inclusions (2B4 antibody, red) are seen in intra-
and extra-nuclear compartments in the striatum (A), hippocampus (B), cortex (C) and cerebellum (D). (E) and (F) show the cortex and cerebellum, respectively,
at higher magniﬁcation revealing the heterogeneous size and location of htt inclusions. Scale bars for (A–F) are as follows (in mm): 20, 50, 50, 50, 10 and 10.
Nuclei are stained blue by DAPI.
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obvious difference is the promoters used to drive the mutant
htt transgenes. The Shortstop mouse is driven by 25 kb of
upstream human htt sequence (9,36). If faithfully regulated
in the mice, this transgene would be expressed beginning at
embryonic day (E) 6.5 in the epiblast, at  E8.5 in embryonic
and extra-embryonic mesoderm (37), and throughout the CNS
by E10 (38). The prion promoter, used to drive htt cDNA in
our mouse models of HD, is activated throughout the CNS
in all cell types by E13.5 (39). Because the prion promoter
is activated later than the htt promoter, it is difﬁcult to con-
clude that early developmental expression of N118-82Q in
our HD118-eGFP mice produced some abnormality that
induced the observed phenotypes. However, it remains very
possible that differences in the distribution of gene expression
accounts for the observed differences. For example,
expression of an exon-1 fragment of mutant htt speciﬁcally
in forebrain produces widespread inclusion pathology, but
the authors did not report evidence of weight loss or abbre-
viated lifespans (40). Thus, it is quite possible that expression
of mutant htt in a particular subset of neurons or in a particular
visceral tissue is required to induce the phenotypes observed in
the HD118-eGFP, HD-N171-82Q and R6/2 mouse models.
In regard to expression in visceral tissues, abnormalities in
the transcriptional regulation of uncoupled protein 1 in brown
fat have been implicated in contributing to the early death of
the HD-N171-82Q and R6/2 models by disturbing thermore-
gulation (41). Notably, transgenic mice harboring a mutant
human htt YAC with 72Q repeats mice do not show such
abnormalities (41) despite the presence of widespread
inclusion pathology composed of N-terminal fragments of
mutant htt that are similar to the R6/2 and HD-N171-82Q
Figure 6. Comparison of htt inclusion pathology in HD-N171-82Q line 81, HD171-eGFP#2 and HD118-eGFP line S22 mice. (A) Brain sections from
HD-N171-82Q line 81 mice show htt inclusions (left, red) are ubiquitinated (middle, green) and intranuclear (right, merged with DAPI). (B) Brain sections
from line HD171-eGFP#2 mice show nearly identical htt/ubq intranuclear pathology. In some cases, nuclear borders are indicated with dashed white lines.
The arrows in (A) and (B) indicate a typical inclusion. (C) HD118-eGFP line S22 brains also exhibit htt inclusions that are ubiquitinated (left and middle
panels, respectively). However, it is common to observe inclusions outside of the nucleus, as indicated by the arrow (right panel).
Table 1. Summary of four transgenic HD mouse models
Mouse lines Aggregates Premature death? Reduced weight
Size Location Ubq (+) Body Brain
N171-82Q line 81 Small Nucleus Yes  6 months Yes Yes
N171-82Q + eGFP line HD eGFP #2 Small Nucleus Yes  20 months N/D N/D
Shortstop Small Nucleus N/D No N/D No
N118-82Q line S22 Small, medium, large Nucleus, cytoplasm Yes  4 months Yes Yes
N/D, not detected, measured.
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pattern of expression similar to that of the YAC72 mice. Thus,
it seems likely that differences in the pattern of transgene
expression between the Shortstop and the HD118-eGFP
mice could underlie the observed differences in phenotypes.
Another possible explanation for the different phenotypes in
the Shortstop and HD118-eGFP mice is differences in the htt
transgene expression level. In comparison to endogenous htt
mRNA, the Shortstop mice express the htt transgene
 3-fold higher than endogenous htt, whereas the YAC128
mice express htt transgene mRNA at  3.75-fold higher than
endogenous htt mRNA (42). This same study also showed
that the HD-N171-82Q line 81 mice express much higher
levels of transgene mRNA than either the Shortstop or
YAC128 mice (42). Thus, it is quite possible that the level
of expression of the N118-82Q gene in our HD118-eGFP
mice is higher than that of the Shortstop mice, and the
higher expression level explains the severity of the phenotype
in our equivalent to the Shortstop mice. Importantly, however,
we show that the HD118-eGFP mice develop abnormalities
much earlier than the HD171-eGFP mice with comparable
levels of mRNA expression, suggesting that the N118-82Q
protein possesses greater toxicity. Given the severity of the
inclusion pathology that was reported in the Shortstop mice
(9), it is difﬁcult to conclude that levels of expression alone
account for the different phenotypic outcomes.
One ﬁnal possibility to explain the different outcomes in our
HD118-eGFP mice and the Shortstop mice is the difference in
background strains of the mice that harbor the transgenes. Our
HD118-eGFP mice are maintained on a B6C3F1/J back-
ground, while the Shortstop mice are on the FVB/N back-
ground. Moreover, like the Shortstop mice, premature death
and weight loss are not prominent features in YAC128 and
BACHD transgenic mice, which are also on the FVB/N back-
ground (26,27). Although the initial descriptions of the
YAC128 mice did not indicate premature death as a pheno-
type, subsequent reports indicated that male YAC128 mice
show slightly shortened lifespans (43). However, this pheno-
type was dependent upon the host strain for the transgene as
breeding to C57BL/6 or 129Sv mice produced YAC128
mice with normal lifespans (44). Furthermore, HdhQ111
knock-in mice backcrossed onto FVB/N, C57BL/6 or 129Sv
strains showed a modulation in intergenerational and
somatic instability of the polyglutamine repeat; and aggrega-
tion of mutant htt in striatum (45). Lifespan and weights
were not measured in this study. Thus, there is evidence to
suggest that the differences in phenotypes of our
HD118-eGFP mice and the Shortstop mice might also be
explained in part by differences the way the strains of mice
used may regulate expression of transgenes or by differences
in responses to mutant htt expression.
Insummary,we demonstratethattransgenic expression ofan
htt fragment that is equivalent to the ﬁrst two exons of htt with
82glutaminerepeatsproducesneurologicabnormalitiessimilar
to previously described HD mouse models. Our ﬁndings con-
trast the initial report of Shortstop mice described by Slow
et al.( 9), which were reported to develop inclusion pathology
without neurological consequences. This report was viewed as
evidence that inclusions formed by mutant htt fragment were
not necessarily toxic or that short fragments of mutant htt
were less toxic than full-length mutant htt. One explanation
for the lack of phenotypes in the Shortstop mice was the possi-
bility that the length of the htt fragment was critical with the
shortstopfragmentbeinglesstoxicthannaturallyderivedhttN-
terminalfragments(21).However,ourﬁndingssuggestthatthis
explanation is not sufﬁcient and that other factors must be
involved. The simplest explanation is that either the level or
pattern of transgene expression in the Shortstop mice spared
CNS structures that are critical in producing the phenotypes
seen in other transgenic mouse models of HD based on
expression of mutant N-terminal fragments of htt.
MATERIALS AND METHODS
All animal experiments described were approved by the Uni-
versity of Florida Institutional Animal Care and Use Commit-
tee. Mice were kept on a 14 h:10 h light to dark ratio and had
ad libitum access to food and water.
Generation of transgenic mice
All transgenic mice were produced by injecting transgene
vectors into single cell embryos produced by mating F1
C57Bl/6J x C3He/J mice. All lines of transgenic mice were
maintained by mating male transgene positive mice with
female NTg F1 C57Bl/6J x C3He/J mice.
The htt cDNA genes were expressed from the MoPrP.Xho
vector, which has previously been described (32). The
Mo.PrP-htt-N171-82Q vector has been previously described
(8). To make the N118-82Q cDNA, a GC-RICH polymerase
chain reaction (PCR) system (Roche, Indianapolis, IN, USA)
was used to amplify DNA from an htt-N171-82Q cDNA tem-
plate. Primers had XhoI restriction sites (underlined) engin-
eered to ﬂank the ampliﬁed cDNA: PrP-Xho/ATG-S,
5′-CGCTCGAGCCACCATGGCGACC-3′; Htt-N119Z-AS,
5′-GCCTCGAGTTATCTGACAGACTGT-3′. The PCR
product was blunted with Klenow enzyme (New England
Biolabs, Ipswich, MA, USA), ligated into pBluescript vector
and then excised by XhoI and subcloned into the XhoI site
of the MoPrP.Xho vector. The N118-82Q coding region was
sequenced at the University of Florida Interdisciplinary
Center for Biotechnology Research to conﬁrm codons and
number of glutamines.
The Keratin14-eGFP expression vector (Supplementary
Material, Fig. S1) was made by amplifying the Keratin14 pro-
moter from pG3Z-K14 (a generous gift from Elaine Fuchs,
Rockefeller University) using the following primers:
5′-CCGGATCCGCGGCCGCCTCCGGAGCTTCTATTCC-3′
and 5′-CCGGATCCTAAATTGGAAAGGGATGCGAGTG
C-3′. The 2 kb amplicon was digested with BamHI (underlined
sequence)andligatedintothePrP-Tetpromotervector,whichis
a variation of the MoPrP.Xho vector in which the PrP promoter
elements have been replaced by the tetracycline operator as
previously described (29). The tetracycline operator is ﬂanked
byBamHIrestrictionsites,allowingforeasyexcisionandrepla-
cement. Orientation of the K14 promoter was veriﬁed by
sequence analysis. The eGFP cDNA was excised from its
vector (Clontech #6086-1, Accession #U55761) and ligated
into the XhoI cloning site of the new K14.PrP.Xho vector.
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Genomic DNA was extracted from tail biopsies and used to
conﬁrm integration of the PrP-N118-82Q transgene. Approxi-
mately 200 ng of genomic DNA was ampliﬁed with the fol-
lowing primers in one reaction: PrP-SJ, 5′-GGGACTATGT
GGACTGATGTCGG-3′; PrP-ASJ, 5′-CCAAGCCTAGACC
ACGAGAATGC-3′; Htt-78-79 SmaI-S, 5′-CCACCCGGGCC
GGCTGTGGCT-3′. The primer pair PrP-SJ and PrP-ASJ
ampliﬁes the endogenous PrP allele ( 750 bp) and the
primer pair Htt-78-79 SmaI-S and PrP-ASJ ampliﬁes the htt
transgene ( 120 bp). eGFP can be detected by eye in live
mouse skin with the use of an excitation lamp (FHS/LS-1B,
BLS Ltd., Budapest, Hungary) afﬁxed to ﬁltered goggles
(FHS/EF-2G2, BLS Ltd.). In the initial screening of lines,
the relative levels of eGFP observed correlated with the rela-
tive ratio of htt transgene to endogenous PrP genes as judged
by the relative abundance of PCR products from genotyping of
tail DNA. To demonstrate eGFP expression in skin, newborn
mice were placed in a Petri dish in a Fuji imaging system
(FUJIFILM Life Science, Stamford, CT, USA). One picture
was taken with bright light and another with UV light. The
resulting images were false-colored with ﬂesh or green tones
depending on the exposure and emission intensity.
Northern blot
Total mouse brain RNA was isolated using the TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). Five microgram of RNA
was electrophoresed in a formaldehyde/agarose gel and trans-
ferred to Genescreen Plus membrane (PerkinElmer, Boston,
MA, USA). For analysis of HD118-eGFP mice, the mem-
branes were incubated with radiolabeled probe (Ready-To-Go
DNA Labeling Beads (-dCTP), GE Amersham, Piscataway,
NJ, USA) using htt cDNA fragment for amino acids 78–118
as a template. This template was generated by PCR using
the aforementioned Htt-78-79 SmaI-S and Htt-N119Z-AS
primers. For analysis of newly generated HD171-eGFP
mice, the RNA blots were incubated with radiolabeled probe
using sequence excised from a cDNA plasmid encoding htt
amino acids 80–171 as the template.
Western blot
Tissues were harvested, weighed and homogenized in
phosphate-buffered saline (PBS) with protease inhibitor cock-
tail (Sigma P8340, St Louis, MO, USA). Tissue homogenate
was then sonicated followed by centrifugation at 16 000g for
5 min. Supernatant protein concentration was determined by
a BCA assay (Pierce, Rockford, IL, USA). For each sample,
10 mg of the total protein was mixed with Laemmli buffer
(46), loaded on 4–20% Tris-Glycine polyacrylamide gels
(Invitrogen), electrophoresed and transferred to a nitrocellu-
lose membrane. To detect eGFP expression, membranes
were incubated with anti-GFP antibody (mJL-8, 1:2000, Clon-
tech, Mountain View, CA, USA) diluted in 5% milk/PBS with
0.01% Tween-20. Bound antibodies were detected with goat
anti-mouse secondary antibodies conjugated to horseradish-
peroxidase followed by chemiluminescence detection on a
Fuji imaging system.
For transfections, HEK293 cells were incubated with htt
cDNAs and Lipofectamine (Invitrogen) diluted in
Opti-MEM (Gibco/Introgen) following the manufacturer’s
protocol. After 48 h, cells were pelleted, lysed in PBS with
protease inhibitor cocktail and clariﬁed by centrifugation at
16000g for 5 min. Protein concentration was determined on
the supernatant and equal amounts of supernatant protein
were loaded on 4–20% Tris-Glycine polyacrylamide gels fol-
lowed by transfer and blotting as previously mentioned.
Immunohistochemistry
Mice were ﬁrst anesthetized and then perfused with PBS.
Extracted brains were ﬁxed by incubation in 4% paraformalde-
hyde in PBS for .48 h at 48C followed by incubation in 30%
sucrose in PBS for .48 h at 48C. Brains were cryosectioned at
30 mm intervals and stored in anti-freeze solution (100 mM
sodium acetate pH 6.5, 1% polyvinylpyrrolidone, 40% ethyl-
ene glycol in dH2O). Sections were then washed in PBS 3 ×
5 min, heated to 908C for 10 min in 10 mM sodium citrate
and 0.01% Tween-20, washed 2 × 5 min in PBS and incu-
bated in 5% normal goat serum (NGS) in PBS with 0.01%
Tween-20. Sections were then incubated in primary antibodies
diluted in blocking buffer (5% NGS + Tween-20), washed
3 × 5 min in PBS, incubated in secondary antibodies with
DAPI (1:2000, Invitrogen), diluted in blocking buffer,
washed 3 × 5 min and mounted on to glass microscope
slides. Sections were covered with Aqua Poly/Mount (Poly-
sciences, Inc., Warrington, PA, USA) and glass cover slips.
Images were taken on an Olympus DSU-IX81 Spinning Disc
Confocal Microscope or Olympus BX60 light microscope.
Primary antibodies used were 2B4 (1:1000, Millipore,
Boston, MA), EM48 (1:500, Millipore) and anti-ubiquitin
(1:250, Dako, Carpinteria, CA, USA). Secondary antibodies
used were goat anti-mouse Alexa Fluor 488 and goat anti-
rabbit Alexa Fluor 568 (1:2000, Molecular Probes/Invitrogen).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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